Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17304219 | 0.88 | MAPT (0.44) | MAPTCYP1A2LMNAALDH1A1GAA | |
| SCHEMBL10913465 | 0.87 | MAPT (0.48) | MAPTLMNAALDH1A1FBP1TSHR | |
| SCHEMBL31586771 | 0.83 | ALDH1A1 (0.45) | MAPTCYP1A2LMNAALDH1A1GAA | |
| SCHEMBL310970 | 0.81 | CYP1A2 (0.49) | MAPTCYP1A2LMNAALDH1A1HSD17B10 | |
| SCHEMBL28086988 | 0.81 | MAPT (0.49) | MAPTLMNAALDH1A1GAAMEN1 | |
| SCHEMBL2945240 | 0.81 | MAPT (0.49) | MAPTLMNAALDH1A1TSHRGAA | |
| SCHEMBL19030212 | 0.81 | CYP1A2 (0.40) | MAPTCYP1A2LMNAALDH1A1KMT2A | |
| SCHEMBL310334 | 0.81 | MAPT (0.46) | MAPTCYP1A2LMNAALDH1A1GAA | |
| SCHEMBL17543791 | 0.79 | MAPT (0.45) | MAPTLMNAALDH1A1FBP1GAA | |
| SCHEMBL31434942 | 0.79 | MAPT (0.45) | MAPTLMNAALDH1A1FBP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336643-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| CN-113493438-B | Tetrahydroisoquinoline compounds | 南京再明医药有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-113493438-A | Tetrahydroisoquinoline compounds | 江苏先声药业有限公司 | 2021-10-12 | — | — | CN | disclosed |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) | 2018-07-17 | — | — | US | disclosed |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) | 2018-07-17 | — | — | US | disclosed |
| US-20170247392-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF | SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO., LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247392-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF | SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO., LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| EP-3150592-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | Beijing Pearl Biotechnology Limited Liability Company (CN) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015180685-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | 北京浦润奥生物科技有限责任公司 | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247392-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF | ALK, BRAF, ABL1 | MAPT 2610/4885CYP1A2 1037/4885LMNA 1070/4885 |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | ALK, BRAF, ABL1 | MAPT 2610/4885CYP1A2 1037/4885LMNA 1070/4885 |
| US-20240336643-A1 | BIFUNCTIONAL COMPOUNDS THAT DEGRADE ALK AND USES THEREOF | ALK, JMJD7, ALKBH3 | MAPT 3459/4885CYP1A2 334/4885LMNA 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.